Trial record 1 of 1 for:    NCT00948467
Previous Study | Return to List | Next Study

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00948467
First received: July 27, 2009
Last updated: July 1, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.


Condition Intervention Phase
Advanced Non-hematologic Malignancies
Advanced Metastatic Melanoma
Drug: TAK-733
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Resource links provided by NLM:


Further study details as provided by Millennium Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Safety profile, dose-limiting toxicities, maximum tolerated dose and recommended phase 2 dose of TAK-733 [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic characterization of TAK-733 [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of food on the pharmacokinetics of TAK-733 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Antitumor activity of TAK-733 in patients with advanced nonhematologic malignancies [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Antitumor activity of TAK-733 in melanoma patients [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 51
Study Start Date: December 2009
Study Completion Date: June 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAK-733 Drug: TAK-733

The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  • 18 years or older.
  • Have one of the following diagnoses: a nonhematologic malignancy for which standard, curative, or life-prolonging treatment does not exist or is no longer effective; OR have stage 3 or stage 4 unresectable melanoma not priorly treated with either MEK or BRAF inhibitor therapy.
  • Melanoma patients should have the V600E BRAF mutation status of their tumor documented, if available, and tumor tissue must be provided for confirmatory genotyping by a central laboratory.
  • Have a radiographically or clinically evaluable tumor.
  • Have suitable venous access for the conduct of blood sampling.
  • Provide voluntary written consent, which can be withdrawn by the patient at any time.
  • Female patients who: are post-menopausal for at least 1 year before screening; OR are surgically sterile; OR if they are of childbearing potential agree to practice two effective methods of birth control from the time of signing the informed consent form through 30 days after the last dose of the study drug, or agree to completely abstain from heterosexual intercourse.
  • Male patients, even if surgically sterilized, must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of the study drug; OR agree to completely abstain from heterosexual intercourse.

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Female patients who are lactating or have a positive serum pregnancy test during the Screening period.
  • Antineoplastic therapy or radiotherapy within 21 days; or nitrosoureas of mitomycin C within 42 days
  • Prior biologic or immunotherapy ≤ 4 weeks prior to enrollment.
  • Grade 2 or greater unresolved toxicity (except alopecia) from previous anticancer therapy.
  • Major surgery within 14 days of the first dose of the study drug.
  • An active infection requiring systemic therapy; or other severe infection.
  • Symptomatic brain metastases.
  • Inability to meet specific laboratory test standards during the Screening period as specified in the study protocol.
  • Human Immunodeficiency (HIV) positive.
  • Hepatitis B surface antigen positive or active hepatitis C infection.
  • Serious medical or psychiatric illness likely to interfere with the study.
  • Uncontrolled cardiovascular condition.
  • Abnormalities on 12-lead ECG performed within 28 days before the start of the study drug that are considered to be clinically significant or rate corrected QT interval > 470 milliseconds.
  • Melanoma patients will be excluded if they have had a diagnosis with or treatment for another malignancy within 2 years of the first dose of the study drug, or have been previously diagnosed with another malignancy with any evidence of residual disease.
  • Treatment with any investigational product within 28 days before the first dose of the study drug.
  • A history of an ongoing or newly diagnosed eye abnormality, such as retinal or corneal pathologies.
  • Abnormal left ventricular ejection fraction (LVEF).
  • Receiving therapeutic anticoagulation
  • Treatment with any of the following strong CYP3A inhibitors or inducers within 14 days before the first dose of study drug: ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, rifampin, rifapentine, or rifabutin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00948467

Locations
United States, Michigan
Wayne State University Karmanos Cancer Institute
Detriot, Michigan, United States, 48201
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00948467     History of Changes
Other Study ID Numbers: C20001
Study First Received: July 27, 2009
Last Updated: July 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Millennium Pharmaceuticals, Inc.:
Advanced nonhematologic malignancies
Advanced metastatic melanoma
BRAF gene

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on October 30, 2014